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a b s t r a c t
Neuraminidase-inhibition (NI) antibody titers can be used to evaluate the immunogenicity of inactiv-
ated inﬂuenza vaccines and have provided evidence of serologic cross-reactivity between seasonal and
pandemic H1N1 viruses. The traditional thiobarbituric acid assay is impractical for large serologic anal-
yses, and therefore many laboratories use an enzyme-linked lectin assay (ELLA) to determine serum NI
antibody titers. The comparability of ELLA NI antibody titers when measured in different laboratories
was unknown. Here we report a study conducted through the Consortium for the Standardisation of
Inﬂuenza SeroEpidemiology (CONSISE) to evaluate the variability of the ELLA. NI antibody titers of a set
of 12 samples were measured against both N1 and N2 neuraminidase antigens in 3 independent assays
by each of 23 laboratories. For a sample repeated in the same assay, ≥96% of N1 and N2 assays had less
than a 4-fold difference in titer. Comparison of the titers measured in assays conducted on 3 different
days in the same laboratory showed that a four-fold difference in titer was uncommon. Titers of the same
sera measured in different laboratories spanned 3 to 6 two-fold dilutions (i.e., 8–64 fold difference in
titer), with an average percent geometric coefﬁcient of variation (%GCV) of 112 and 82% against N1 and
N2 antigens, respectively. The difference in titer as indicated by fold range and %GCV was improved by
normalizing the NI titers to a standard that was included in each assay. This study identiﬁed background
signal and the amount of antigen in the assay as critical factors that inﬂuence titer, providing important
information toward development of a consensus ELLA protocol.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND licenseAbbreviations: CONSISE, Consortium for the Standardisation of Inﬂuenza
eroEpidemiology; ELLA, Enzyme-linked lectin assay;NI, Neuraminidase inhibition;
MT, Geometric mean titer; %GCV, Percent geometric coefﬁcient of variation.
∗ Corresponding author. Tel.: +1 240 402 9505.
E-mail address: Maryna.Eichelberger@fda.hhs.gov (M.C. Eichelberger).
1 Study participants and their afﬁliations are listed in supplementary Table S1.
ttp://dx.doi.org/10.1016/j.vaccine.2015.12.022
264-410X/Published by Elsevier Ltd. This is an open access article under the CC BY-NC-N(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
An enzyme-linked lectin assay (ELLA) that was initially
described by Lambre et al. [1] has been optimized to evaluate
serologic responses to NA [2] and evaluate NA antigenic drift [3].
This assay is more practical than the traditional thiobarbituric acid
assay [4] which quantiﬁes sialic acid released after cleavage by
neuraminidase [5], while the ELLA measures the amount of the
penultimate sugar, galactose that binds to peanut agglutinin (PNA)
when it becomes exposed following release of sialic acid [6]. The
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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LLA is conducted in a 96-well format using PNA conjugated to
n enzyme and a colorimetric substrate. ELLA has recently been
sed tomeasure serumNA-inhibition (NI) antibody titers in a num-
er of clinical studies [7–9], including studies demonstrating that
oth inactivated and live attenuated vaccines have the capacity
o induce NA-speciﬁc antibodies [10,11]. While NI titers correlate
ith resistance against disease [12], the absolute NI titer that offers
rotection against inﬂuenza has not been established.
The CONSISE organization includes a network of laboratories
hat have assessed the comparability of inﬂuenza hemagglutina-
ion inhibition (HI) and microneutralization assays [13]. While
alidation studies of the ELLA have been conducted in individual
aboratories, the comparability of NI antibody titers measured in
ifferent laboratories has not been established. This is an impor-
ant factor when comparing data between assays conducted at
ifferent sites. CONSISE laboratory members from 18 different
ountries, representing academic institutions, commercial organi-
ations, regulatory laboratories, WHO Collaborating Centers (CCs),
nd National Inﬂuenza Centers (NICs), participated in a study of
he inter-laboratory variability of NI antibody titers measured by
he ELLA. The participating laboratories are listed in supplemen-
ary Table S1. Laboratories were provided with an ELLA protocol
2], NA antigens of N1 and N2 subtypes and a set of 12 sam-
les that had been pre-screened for a range of titers against each
ntigen. The samples included 9 different human sera, plasma
rom a cow transgenic for human Ig that had been vaccinated
ith a seasonal inactivated inﬂuenza vaccine (kindly provided by
anford Applied Biosciences, Sioux Falls, South Dakota, USA) and
uriﬁed human intravenous immunoglobulin (IVIG, kindly pro-
ided by Baxter Biomedical Research, Austria); the IVIG sample
as duplicated in the panel in order to examine assay repeat-
bility. The participating laboratories measured NI antibody titers
n all the samples in 3 replicate assays against both N1 and N2
ntigens.
Statistical analysis was performed to evaluate the variability of
itersmeasured in each assay (assay repeatability), the variability of
iters from three assays performed in the same laboratory ondiffer-
nt days (intra-laboratory variability), and the variability of titers
rom three assays performed in all of the participating laboratories
inter-laboratory variability). Analysis of the data was performed
n order to identify assay parameters that reduced variability or
mproved performance.
. Methods
.1. ELLA protocol
A published protocol [2] was distributed to all participat-
ng laboratories. Brieﬂy, all samples were heat-treated at 56 ◦C
or 45min prior to serial two-fold dilutions in PBS. Equal vol-
mes of sample and a predetermined amount of antigen were
ixed and then transferred to 96-well plates coated with fetuin
Sigma-Aldrich, St. Louis, MO, USA). The plates were covered and
ncubated at 37 ◦C overnight (18–20h). After washing the plates,
eanut agglutinin conjugated to peroxidase (Sigma-Aldrich, St.
ouis, MO, USA) was added. Plates were incubated at room tem-
erature for 2h in the dark and washed before the addition of
-phenylenediamine dihydrochloride (OPD) substrate. Some par-
icipants used 3,3′,5,5′- tetramethylbenzidine (TMB) as a substrate.
he reaction was stopped by adding 1N H2SO4 and the absorbance
as read at 490nm (OPD) or 450nm (TMB). The NA inhibition (NI)iter was expressed as the reciprocal of the highest dilution that
xhibited ≥50% inhibition of NA activity (50% end-point titer) or
he 50% inhibition concentration (IC50) that was determined by
our-parameter non-linear regression analysis.ine 34 (2016) 458–465 459
2.2. Study design
Each laboratory ran a set of 12 samples against N1 and N2 anti-
gens in 3 independent assays. In instances when the distributed
protocol could not be followed completely, the laboratory reported
the modiﬁcation together with the results. Some laboratories pro-
vided 2 sets of data: one following the distributed protocol and the
other following an in-house ELLA protocol.
A study worksheet reporting the NI antibody titers measured
in each assay as well as the assay conditions used by participating
laboratories, was submitted to the lead laboratory and statistician.
Results from laboratories that did not perform 3 replicate assays
(data setM1)ordidnotuse thedistributedantigen (datasetsN2,O1,
andO2)were excluded from the analysis. Even though the reported
results indicated that some assays did not meet all qualiﬁcation
criteria, all data from assays using the distributed sera and antigens
were included in the analysis of variability. Each laboratory was
assigned a letter code, with each dataset assigned a number. For
example, laboratory H provided 2 datasets, one set of results was
generated following the designated study protocol, and the second
set of results was generated following an in-house ELLA procedure.
2.3. Study samples
The lead laboratory measured NI antibody titers in a panel of
de-identiﬁed sera that had previously been used for HI assays
[14]. These sera were collected from volunteers who had been
vaccinated with an inactivated split 2009/10 seasonal inﬂuenza
vaccine. Eight samples were selected for use in the ELLA study:
these ranged in NI titers against N1 and N2 antigens of sea-
sonal H1N1 inﬂuenza virus A/Brisbane/59/2007 (BR/07) and H3N2
virus A/Uruguay/716/2007 (UR/07), the antigens contained in the
2009/10 trivalent inﬂuenza vaccine. Other samples included in the
study panel were a commercial human serum pool (Lonza, Basel,
Switzerland) with a low NI antibody titer against each antigen, a
preparation of puriﬁed human immunoglobulin (kindly provided
by Baxter Biomedical Research, Austria) with high NI antibody
titer against each antigen, and cow plasma obtained from an ani-
mal transgenic for human immunoglobulin genes that had been
vaccinated with the 2012/2013 trivalent inﬂuenza vaccine (kindly
provided by Sanford Applied Biosciences, USA). Within the set,
one sample was repeated, resulting in a set of 12 samples tested
in each study assay. The samples were labeled as S001–S012 and
shipped to participating laboratories on dry ice. Sample identities
weremaintained blind and their identitieswere revealed, as shown
in Supplementary Table S2, only after the data had been submitted
for statistical analysis.
2.4. Antigens
The antigens used in ELLA were in the form of inactivated reas-
sortant H6N1 and H6N2 whole viruses. These reassortant viruses
were generated by reverse genetics as previously described, with
each reassortant expressing the targeted NA antigen, the HA of
an avian H6 virus, and all other proteins from A/PR/8/34 [15].
The viruses were cultured in 9–12 days old speciﬁc-pathogen-free
embryonated chicken eggs (Sunrise Farms, NY, USA) and inactiv-
ated by incubation with beta-propiolactone (BPL) for 4h at 4 ◦C
prior to inactivating residual BPL at 37 ◦C for 30min. Inactivation
of the virus was conﬁrmed by serial blind-passage in eggs. Virus
aliquots were stored at −80 ◦C. Prior to performing the assay, each
laboratory titrated the antigen in order to determine the appropri-
ate dilution to be used.
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Table 1
Intra-laboratory assay variability: number of samples that had ≥four-fold differ-
ence in 50% end-point or IC50 titer when run in three independent replicate assays
(n=12).
Number of sera with titers that were ≥four-fold different against
H6N1 H6N2
Lab 50%
end-point
IC50 50%
end-point
IC50
A 0 0 0 0
B 0 NAa 0 NA
C 0 0 1 0
D 1 0 1 0
E 0 0 0 0
F 1 0 1 0
G 0 0 0 0
H1 0 0 0 0
H2 2 0 0 0
I 3 0 2 2
J 0 1 0 1
K 0 0 0 0
L 1 0 4 0
M2 0 0 0 0
N1 0 1 0 1
P 2 0 0 1
Q 0 0 0 0
R 0 0 0 0
S 0 0 0 0
T 0 0 0 0
U 0 0 0 0
T
I60 M.C. Eichelberger et al.
.5. Statistical analysis
Within-assay repeatabilitywas assessedby comparing the titers
f samples 1 and 10 reported in each assay, since these were
dentical. The variability of titers generated within each labora-
ory (intra-laboratory variability) was evaluated by comparing the
iters measured in three independent assays by the same operator.
o measure the variability of titers reported by different labo-
atories for each of the 12 samples (inter-laboratory variability),
he geometric mean titers (GMTs), the geometric standard devia-
ion (GSD), and percent geometric coefﬁcient of variation (%GCV)
cross laboratories were calculated; GSD=exp(SD(log titer)) and
GCV=100(GSD−1). When there is no variation, GSD=1 and
GCV=0.
. Results and discussion
.1. Assay repeatability
Assay repeatability was assessed by determining the ratio of the
0% end-point titers for the same sample that had been duplicated
n the study set (i.e., S001 and S010). The ratios were determined
or the 3 assays conducted in each laboratory. In 69 of 71 N1
ssays (97%) and 68 of 71 N2 assays (96%), the difference in titer
etween S001 and S010 was two-fold or lower (Supplementary
able S3).
.2. Intra-laboratory assay variability
Intra-laboratory assay variability was assessed in each lab-
ratory by evaluating the fold differences in 50% end-point
I titers measured for all 12 samples across three inde-
endent assays. Differences in IC50 titers reported in assays
onducted in the same laboratory on different days, was also
onsidered (Table 1). The majority of laboratories reported
esults in which the difference across independent assays in
I antibody end-point titers for all samples was <four-fold
15 and 16 of the 23 datasets for the N1 and N2 antigens,
espectively). When differences in titers reported as IC50 were
ompared, thevariabilitywas even lower,with18of the21datasets
aving titers against the N1 antigen that were <four-fold different
n repeat assays for all 12 samples and 17 of 21 IC50 datasets had
iters against N2 that were <four-fold different across independent
ssays for all 12 samples.To examine the beneﬁt of calculating the IC50, the difference
n variability in all results using 50% end point analysis and IC50
as assessed for all datasets and all samples. For H6N1, the dif-
erence in assay variability determined using the 50% end-point
able 2
nter-laboratory variability assessed as %GCV and fold range of absolute (Abs.) and norma
%GCV
Sample Abs. N1 Normalized N1 Abs. N2 Normalized N2
1 95 69 60 43
2 168 0 96 60
3 111 49 84 57
4 98 65 98 106
5 123 50 75 47
6 87 69 64 52
7 90 65 74 53
8 96 55 74 0
9 114 54 114 73
10 116 56 84 54
11 119 53 80 43
12 130 61 80 58
Mean 112 59 82 59V 1 1 1 0
W 1 NA 2 NA
a NA, not applicable because the IC50 values were not provided for this dataset.
and IC50 titers was statistically signiﬁcant (p=0.021), while the
corresponding difference in assay variability for H6N2 was not sig-
niﬁcant (p=0.854).
3.3. Inter-laboratory assay variability
3.3.1. Overall inter-laboratory assay variability
Variability in NI titers measured in different laboratories was
assessed by examining the differences in GMTs in datasets sub-
mitted by each laboratory for each of the 12 samples regardless of
whether the assay had met all acceptance criteria speciﬁed in the
protocol. The 50% end-point GMT of each sample in all datasets is
shown for the N1 antigen in supplementary Table S4 and the N2
antigen in supplementary Table S5. The variability in titer across
laboratories (%GCV) is shown in Table 2. Dataset M1 was excluded
because assays were not repeated 3 times; datasets N2, O1, and
O2 were excluded from the analysis because the assays were sig-
niﬁcantly different from the distributed protocol (used different
antigens and/or a signiﬁcantly different method). When taking all
lized geometric mean NA inhibition titers against N1 and N2 antigens.
Fold range (log2)
Abs. N1 Normalized N1 Abs. N2 Normalized N2
3.3 3.0 3.0 2.0
5.3 0 3.0 2.7
4.5 2.2 3.7 2.5
3.6 2.4 4.3 5.0
3.9 2.5 3.0 2.1
2.8 2.5 2.4 2.0
3.3 2.7 3.3 2.7
3.2 2.7 3.3 0
3.8 2.2 4.5 3.2
3.9 2.0 3.3 2.7
4.2 2.3 3.2 2.1
4.5 2.1 3.3 2.4
3.9 2.4 3.4 2.7
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Fig. 1. Relative frequency of end-point NA inhibition antibody titers against the N1 antigen for each sample (n=24): the y-axis shows the percent of laboratories that attained
a ter (lo
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uparticular titer; the x-axis shows the lower bound of the GMT of the NI antibody ti
.3 includes GMTs of 27.3 to <28.3 (160 to <320).
emaining datasets into account, the mean %GCV across 12 sam-
les for 50% end point titers against the N1 antigen was 112% and
gainst theN2 antigenwas 82%. The variability in titers across labo-
atories was greater for assays using the N1 antigen than for assays
sing the N2 antigen (p=0.00094, 2 sample t-test).g2) reported for the 3 assays conducted in each laboratory, i.e., a value on x-axis of
To assess whether assay variability was related to the NI anti-
body titer, the correlation between NI antibody titer (log2) and
%GCV was evaluated (Supplementary Figure S1). The correlation
coefﬁcients between GMT and %GCV suggested that there was
a positive relationship between the titer and variability for the
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Fig. 2. Relative frequency of end-point NA inhibition antibody titers against N2 antigen for each sample (n=24): the y-axis shows the percent of laboratories that attained a
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f 7.3 includes GMTs of 27.3 to <28.3 (160 to <320).
1 antigen, but the relationship was not statistically signiﬁcant
R2 =0.161). The relationship was even poorer for the N2 antigen
R2 =0.036), showing that there is little association between vari-
bility and the magnitude of the titer.Table 2 also shows the range (in log2 scale) in titers for each
ample. The relative frequency of end-point NI antibody titers for
ach serum sample is shown in Fig. 1 for the N1 antigen and in
ig. 2 for the N2 antigen. The titers of the same sera measured in2) reported for the three assays conducted in each laboratory, i.e., a value on x-axis
different laboratories spanned 3 to 6 two-fold dilutions, i.e., 8 to 64
fold difference in titer. In most instances, the distribution of titers
measured followed a bell-shaped curve, with the greatest number
of laboratories measuring the median titer.3.3.2. Normalizing the data reduces assay variability
Samples that had moderate NI antibody titers against N1 and
N2 antigens were selected to normalize the data; sample S002
/ Vacc
w
w
t
i
r
t
c
i
s
[
a
t
t
w
r
s
l
l
3
i
l
t
v
m
a
f
i
r
l
m
m
g
w
L
d
G
u
(
s
T
P
i
m
o
aM.C. Eichelberger et al.
as elected to normalize titers against the N1 antigen, and S008
as elected to normalize the titers against N2. The normalized
iters are shown in supplementary Tables S6 and S7. The variability
n end-point titer was reduced when the GMTs were normalized,
esulting in an average reduction in %GCV from 112 to 59 and 82
o 59 for N1 and N2 ELLAs, respectively (Table 2). This improved
onsistency in normalized titers (50% reduction in average %GCV),
s similar to the reduced variability observed in inter-laboratory
tudies of hemagglutinin inhibition andmicroneutralization assays
16,17]. Except for the NI antibody titer for S004 against the N2
ntigen, all of the ranges in titers measured in different labora-
ories against both the N1and N2 antigens were reduced when
he data were normalized; the average range (log2) of N1 titers
as reduced from 3.9 to 2.4 and the range of N2 titers was
educed from 3.4 to 2.7 (Table 2). These data suggest that serum
tandards should be developed and made available for use in sero-
ogy studies as a means to compare results generated in different
aboratories.
.3.3. Assay parameters that impact variability of titers measured
n different laboratories
A review of the assay conditions used by each participating
aboratory identiﬁed some parameters that may have contributed
o differences in titers reported and hence inter-laboratory assay
ariability. The assays differed in the amount of antigen used, the
aximum signal in each assay (i.e., the signal of antigen (inactiv-
ted virus) alone), the signal to noise ratio and the substrate used
or colorimetric read-out. To examine whether these differences
mpacted the titers and assay variability across different laborato-
ies, the mean GMTs and %GCV between subgroups of participating
aboratories were compared (Table 3). The overall GMT (geometric
ean of titers from 12 samples tested) and %GCV for assays that
et the acceptance criteria (acceptable signal strength and back-
round <10% of the positive signal) and followed the given protocol
ith the exception of substrate, were compared; datasets A, E, H1,
, andN1usedOPDas substrate (shownasGroup1 in Table 3)while
atasets B, H2, I, K, and M2 used TMB as the substrate (shown as
roup 2 in Table 3). The GMTs as well as %GCVs for results reported
sing OPD and TMB for both H6N1 and H6N2 antigens were similar
p≥0.06). The reproducibility in results for assays using different
ubstrates is exempliﬁed by datasets provided by laboratory H that
able 3
otential factors affecting inter-laboratory variability of results: comparison of geometric
n multiple laboratories using different acceptance criteria, substrates, or antigen amount
End-point measured
Factor GMT: mean± SDa
Group 1 G
Assays using the H6N1 antigen
Substratec 81±4.9 9
Background signald 93±5.2 1
Positive signal strengthe 99±5.3 1
Antigen amountf 106±5.3 8
Assays using the H6N2 antigen
Substratec 94±6.1 1
Background signald 115±5.8 1
Positive signal strengthe 112±6.2 1
a The geometric mean titers and standard deviations (SD) were calculated for Groups 1
b The % geometric coefﬁcient of variation and SD was calculated for Groups 1 and 2 as t
c Group 1: datasets A, E, H1, L, and N1 used OPD; Group 2: datasets B, H2, I, K, and M2 u
d Group 1: A, B, E, G, H1, H2, I, J, K, L, M1, M2, and N1 had background values ≤10% o
aximum signal.
e Group 1: A, B, D, E, H1, H2, I, K, L, M2, and N1 (maximum signal ≥1.7); Group 2: C, G,
f Group 1: datasets A, B, D, H1, H2, I, K, L, M1, M2, and N1 that used ≥1:60 dilutions o
f antigen i.e., less dilute (<1:60) antigen stock. Both Groups 1 and 2 datasets used simila
ntigen amounts was not possible.ine 34 (2016) 458–465 463
used OPD and TMB in parallel assays (datasets H1 and H2 respec-
tively, Supplementary Tables S4 and S5).
To determine whether the titers and variability were impacted
by background values, the GMT and %GCV were calculated for
results reported from assays thatmet the background signal accep-
tance criterion (≤10% of positive signal strength) or had >10%
background values, shown as Group 1 and Group 2 in Table 3,
respectively; Group 1 included datasets A, B, E, G, H1, H2, I, J, K,
L, M1, and M2 and Group 2 included datasets C, D, and V. The GMT
of 50% end-point titers against N1 and the %GCV in both N1 and
N2 assays were statistically greater when the background signal
was higher than recommended (p≤0.02). This suggests that lab-
oratories should adhere to this parameter as an assay acceptance
criterion, particularly if data are to be compared between different
laboratories.
Some laboratories reporteddata fromassays inwhichmaximum
absorbancewas<1.7,while othershadmaximumabsorbance levels
of up to 4.0. To determine whether titers obtained in assays with
lowmaximumsignal strengthwere signiﬁcantly different to assays
inwhich signal strengthwas≥1.7,GMTsand%GCVswerecompared
between A, B, D, E, H1, H2, I, K, L, M2, and N1 (Group 1, maximum
signal ≥1.7) vs. C, G, J, andV (Group 2,maximumsignal <1.7). Signal
strength did not have a signiﬁcant impact on either GMT (p=0.75
and 0.07 for N1 and N2 antigens, respectively) or %GCV (p=0.39
and 0.57 for N1 and N2 antigens, respectively).
Titration of antigen before conducting the ELLA is critical as this
allows the user to identify the dilution of antigen to use in the
assay. The antigen titration should yield absorbance values that
result in an S-shaped curve, with the signals at low virus dilu-
tions forming a plateau that is followed by a linear relationship
between virus dilution and signal. Published studies show that the
amount of antigen used in the ELLA is critical for assay robust-
ness, with consistent titers measured when the amount of antigen
used in the assay is within the linear range of the virus (antigen)
titration curve [2,3]. The assay protocol that was distributed to
study participants gave instructions to use a dilution of virus (anti-
gen) that gives 90–95% of maximum activity, however the dilution
of H6N1 antigen that was selected differed between laboratories
because the antigen titrations and analytical tools were not the
same. To determinewhether using different amounts of H6N1 anti-
gen impacted assay variability, GMTs and %GCVs of datasets A, B, D,
mean NI antibody titers (GMT) and assay variability (%GCV) for assays performed
s.
%GCV: mean± SDb
roup2 Group 1 Group 2
0±5.6 80±20 137±39
29±5.2 105±18 233±103
04±5.1 131±31 128±36
4±4.9 117±27 137±22
14±6.3 77±23 77±34
29±5.7 84±20 151±37
37±5.1 89±18 115±37
and 2 using the mean GMT of all samples in each dataset included in the group.
he arithmetic mean of the %GCV reported for datasets within each group.
sed TMB.
f maximum signal; Group 2: datasets C, D, and V had background values >10% of
J, and V (maximum signal <1.7).
f the H6N1 antigen; Group 2: datasets C, E, G, J, and V that used greater amounts
r dilutions of H6N2 antigen and therefore comparison of data from different H6N2
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1, H2, I, K, L, M1, M2, and N1 (Group 1) from assays that used
1:60 dilution of the H6N1 antigen and datasets C, E, G, J, and
(Group 2) from assays using a greater amount of H6N1 anti-
en (i.e., less than a 1:60 dilution), were compared. The average
MTs from assays with more antigen were signiﬁcantly lower than
MTs reported in datasets using less antigen (p=0.05, ANOVA tak-
ng into consideration sample variability). The variability in results
as statistically similar for Groups 1 and 2. While the data from
his study are insufﬁcient to draw a conclusion regarding the sen-
itivity of ELLA under different conditions, others have pointed out
hat use of excessive amounts of antigen in the ELLA is likely to
educe the sensitivity of the assay [2,3]. All laboratories used a sim-
lar amount of N2 antigen (the stock was diluted 1:20 or 1:40),
nd therefore an analysis to evaluate the impact of antigen dilu-
ion on NI antibody titers against N2 could not be tested. These
esults conﬁrmthe importanceof using anamountof antigen that is
ithin the linear range of the titration curve. The protocolwas con-
equently revised to indicate that a dilution of virus that gives 90%
f maximum signal should be used, with a recommendation to use
our-parameter logistics to determine antigendilution to beused in
ssays.
This international study provided an opportunity for labora-
ories that had not previously conducted the ELLA, to become
roﬁcient in measuring NI antibody titers. Discussion among the
articipants also identiﬁed improvements that canbe implemented
n future assays. For example, a buffer that has a pH at which NA
nzyme activity is optimal allows the assay to be performed in a
horter time period [9], and recombinant NA [18] or VLPs [8,9] can
e used as a source of antigen, thereby bypassing the need to gen-
rate H6 reassortants. Future studies will be needed to evaluate
hether assays performed with improved conditions or with dif-
erent types of antigens, yield results that are comparable with the
LLA protocol used in this study.
. Conclusions
Assay repeatability as well as intra- and inter-laboratory vari-
bility was assessed in an international CONSISE study of the
LLA. The NI titers of samples repeated within the same assay
iffered by no more than 2-fold. Assays repeated within the
ame laboratory gave consistent results, with most datasets hav-
ng <four-fold differences in titer. As expected, there was greater
ariability in titers across different laboratories than within each
aboratory. Although up to a 64-fold difference in NI antibody
iter was observed, this is lower than differences in hemagglu-
ination inhibition and microneutralization titers measured in
ifferent laboratories (the range of titers was 80-fold for HI titers
nd 109-fold for microneutralization assays) [17]. The variabil-
ty of NI antibody titers measured in different laboratories was
lso reasonable, with %GCV that was reduced further by normal-
zing the NI antibody titers to the titer of a sample elected as a
tandard that was run in every assay. Comparison of the results
eported by different laboratories conﬁrmed that the amount of
ntigen used in the assay is a critical parameter, and therefore
hould be carefully established by repeat titrations prior to per-
orming ELLA. The analysis also suggests that data should only be
ccepted from assays that meet the background acceptance cri-
erion (background should be ≤10% maximum positive signal).
lthough the data suggest the current assay has low variability
nd is robust, further assay improvements, such as the use of
ecombinant antigens or establishment of conditions that allow
horter incubation times, are anticipated. Such improvements
ill further enable the measurement of NI antibody titers and
ssessment of these antibodies as a correlate of immunity against
nﬂuenza.
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